Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Oral Zenagamtide With Different Meal/Water Timings in Overweight or Obesity
NCT07815067Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1 trial of amycretin in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve at Steady State at Day 224. Started Sep 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07815067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815067.